Clinical Trials Browser

amivantamab × 30 days × Clear all

NCT02609776 2026-06-05

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05379595 2026-06-05

OrigAMI-1

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05488314 2026-06-05

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-06-05

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-06-05

PolyDamas

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-06-05

COCOON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06385080 2026-06-05

OrigAMI-4

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06662786 2026-06-05

OrigAMI-2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06667076 2026-06-05

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06750094 2026-06-05

OrigAMI-3

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07227025 2026-06-05

KaRAnaSa

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07276399 2026-06-05

OrigAMI-5

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Phase 2 Suspended

Locally Recurrent Skin Squamous Cell Carcinoma

NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT07586202 2026-05-14

AmiNA

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung